Drug Resistance and Novel Targets for Cancer Therapy—Second Edition

Dear Colleagues,

Drug resistance is a complex phenomenon resulting from one or more mechanisms which render cells resistant to anticancer drugs. Molecular hallmarks of cancer and therapeutics against drug resistance mechanisms are the leading targets for cancer treatment. Molecular targeted therapy is gaining attraction due to its specificity to cancer while sparing normal cells. Despite this, drug resistance still representsa major obstacle that limits sustained clinical benefits not only to targeted cancer therapies, but also conventional chemotherapy. Notably, while some cancer patients do not respond to anticancer drugs due to primary resistance, even responders might eventually relapse following acquired resistance.

 In this context, we are proposing a new Special Issue encompassing these two major molecular pathways involved in cancer treatment such as the determinations of new cancer related molecular targets, development of drugs that block them and drugs that aims resistance to treatment. We invite innovative research papers and review articles discussing new molecular targets or anticancer drugs. We encourage articles related, but not restricted to Apoptosis Induction, Proliferative Signaling, Migration, Angiogenesis, Metastasis, Immune Checkpoint, Tumor Vaccine Related Targets, Chimeric Antigen Receptor T-Cell or their possible drug resistance mechanisms. Therefore, this special issue is aimed to approach novel molecular targets, their bullets and possible resistance mechanisms that might be targeted to potentiate more durable and effective responses for cancer therapy.

Dr. Bruno Kaufmann Robbs
Dr. Fernando de Carvalho da Silva
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer
• drug resistance
• targeted therapy
• conventional chemotherapy
• natural products
• molecular targets
• cancer hallmarks
• therapeutic agents

• Drug Resistance and Novel Targets for Cancer Therapy in Biomedicines (26 articles)